COMP <GO>
AMGN vs GILD // FORWARD P/E MULTIPLE
Amgen Inc. (NASDAQ) VS. Gilead Sciences Inc. (NASDAQ) • 15-METRIC TALLY: AMGN 4
— GILD 9
▲ FORWARD P/E MULTIPLE LEADER: GILD
LAST: $466.01 (+1.15%) • MKT CAP: $249.09B
forward-pe
30.0x
LAST: $170.68 (+3.06%) • MKT CAP: $205.35B
forward-pe
22.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMGN VS. GILD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMGN | GILD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.20% | 78.80% | -11.60 | GILD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.50% | 21.00% | -6.50 | GILD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 27.2x | 21.0x | +6.20 | GILD | /valuation <GO> |
| Free Cash Flow Yield | 3.25% | 4.60% | -1.35 | GILD | /fcf-yield <GO> |
| Operating Margin | 24.70% | 34.00% | -9.30 | GILD | /operating-margins <GO> |
| Net Profit Margin | 21.00% | 28.90% | -7.90 | GILD | /net-margins <GO> |
| Revenue Growth (YoY) | 10.00% | 2.40% | +7.60 | AMGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.06% | 1.95% | +0.11 | AMGN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 5.87 | -2.04 | GILD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.0 | 64.3 | +2.70 | AMGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.88 | -0.01 | GILD | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 30.0x | 22.4x | +7.60 | GILD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $249.09B | $205.35B | $43.74B | AMGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMGN REV | GILD REV | AMGN GROSS % | GILD GROSS % | AMGN FCF | GILD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.75B | $29.44B | 67.2% | 78.8% | $8.10B | $9.46B |
| FY 2024 | $33.42B | $28.75B | 61.5% | 78.3% | $10.39B | $10.30B |
| FY 2023 | $28.19B | $27.12B | — | — | $7.20B | $6.79B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMGN // BETA 0.87
GILD // BETA 0.88